FZD10 and cancer: For example, it is the case of WT1, DLK1, TP73, EEF1A2, IGF1R, DKK1, SPOCK1, ITPKA, HOXA3, NOX4, FZD10, VASH2, GATA2, SOX8. Thus, our genetic studies together with a revisited analysis of human cancer databases reveal that raising dosages of oncogene sets characterised by hypermethylated CGIs is a robust mechanism operating in cancer.